Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Europe

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

All Videos

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

EYLEA 8mg for nAMD and DME Treatment

Partners

Subscribe

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina – Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

1rem

Dr. Marion Munk reviews clinical trials of high-dose aflibercept in neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO), providing insights and discussing the clinical implications derived from these trials.

Aflibercept 8mg in Neovascular AMD and DMO: Insights from PULSAR and PHOTON Trials

Dr Charles Wykoff presents the latest date from the GAIL extension study evaluating pegcetacoplan for treating geographic atrophy.

Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months

Dr Arshad Khanani details the key learnings from the real-world evidence generated in the TRUCKEE and TAHOE studies following the FDA approval of faricimab.

Faricimab in the Real World

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).

Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD

In this Rapid Readout, Dr Paul Hahn shares his presentation from the 2023 ASRS annual meeting. This study compares the efficacy of the two FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of the phase 3 trials.

Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy

Dr Varun Chaudhary shares insights from his presentation at the 2023 ARVO annual meeting, highlighting key findings on personalized treatment interval dosing using faricimab.

Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD

In this Rapid Readout, Dr Jennifer Lim shares her presentation from the 2023 ARVO annual meeting, highlighting the visual and anatomic outcomes observed in clinical trials of faricimab when administered according to a personalized treatment algorithm for patients with diabetic macular edema (DME).

Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing vs Aflibercept in Patients With DME

Dr David Almeida shares insights from his presentation at the 14th Annual Congress on Controversies in Ophthalmology (COPHy) in Lisbon, Portugal.

The TRUCKEE Study: Real-World Efficacy and Safety of Faricimab in Neovascular AMD

Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.

Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.